Search results for "liver toxicity"

showing 3 items of 3 documents

Novel Biocompatible Cationic Copolymers Based on Polyaspartylhydrazide Being Potent as Gene Vector on Tumor Cells

2007

Introduction. The reaction between !,"-poly(aspartylhydrazide) (PAHy), a water soluble synthetic polymer and 3-(carboxypropyl)trimethyl-ammonium chloride (CPTACl) produced copolymers bearing permanent positive charges (PAHy–CPTA) with molecular weight of 10 kDa and PAHy–CPTA copolymers differing in positive charge amount (18–58%) were chosen for biological investigations. Materials and methods. Biophysical properties of DNA/PAHy–CPTA polyplexes were evaluated in terms of DNA condensation, zeta potential and size distribution. Cytotoxicity studies on Neuro2A murine neuroblastoma cells evidenced absence of toxicity of these copolymers up to 300 2g/ml unlike linear polyethylenimine (LPEI) that…

Erythrocyte AggregationBiocompatibilityCell SurvivalPolymersPharmaceutical ScienceBiocompatible MaterialsBiologyTransfectionDNA condensationMiceNeuroblastomachemistry.chemical_compoundIn vivoCationsCell Line TumorZeta potentialAnimalsPolyethyleneiminePharmacology (medical)Particle SizeCytotoxicityPharmacologyPolyethylenimineCytotoxicity liver toxicity nonviral gene delivery transfectionDose-Response Relationship DrugLiver DiseasesBody WeightOrganic ChemistryGenetic transferDNATransfectionMolecular WeightLiverchemistryBiochemistryNucleic Acid ConformationMolecular MedicineFemaleChemical and Drug Induced Liver InjuryPeptidesBiotechnologyPharmaceutical Research
researchProduct

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

Trabectedin-Related Liver Toxicity in Soft Tissue Sarcoma Patients: Always a Good Reason to Discontinue the Treatment?

2014

ABSTRACT Aim: A transient increase in liver enzymes is a well described side effect developed by almost 40% of soft tissue sarcoma (STS) patients treated with trabectedin, often leading to treatment delays or discontinuation. We retrospectively analysed the correlation between trabectedin-related liver toxicity and treatment outcome. Methods: Data from a total of 113 patients receiving trabectedin administered at the dose of 1.5 mg/m2 iv 24 hours in 3 reference centers were evaluated. This exploratory analysis was performed to assess the impact of liver toxicity (grade 3-4 AST and ALT increases) on the trabectedin efficacy and outcome in STS patients. All the patients included had metastati…

Cancer Researchmedicine.medical_specialtyLiver toxicityAnthracyclineSide effectPopulationLiposarcomaGastroenterologyInternal medicinemedicineeducationTrabectedineducation.field_of_studybusiness.industrySoft tissue sarcomaHazard ratioHematologymedicine.diseaseSynovial sarcomaDiscontinuationSurgeryOncologyPremedicationSarcomabusinessmedicine.drugAnnals of Oncology
researchProduct